Previous 10 | Next 10 |
Total net revenue decreased by 4% to $64.1 million in the second quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased slightly to $56.5 million in the second quarter of 2019, compared to the same quarter in 2018. Innoviva, Inc. (NASDAQ:INVA)...
Black swans don't always come alone The following is a fascinating story about two "black swan" events happening at the same time, but one remaining somewhat under the radar, at least until very recently. The combined effect of the two has caused a severe sell-off in the shares of Theravan...
The healthcare sector is underperforming the market by a wide margin on a year to date basis. The Healthcare Select Sector ETF ( XLV ) has gained 5.2%, while the SPDR S&P 500 ( SPY ) is up by almost three times that, with a cumulative gain of 15.1% in the same period. Data by YCharts ...
The small-cap market is unearthing some shares at present that could return for investors in the not too distant future. The recent downturn has hit some stocks hard, but this isn’t something that should scare investors. Rather, now is the time to eye potential while these small-ca...
As I always do as a value investor, I am always perusing different opportunities no matter where the market has taken us. Obviously when the market is overvalued, like it is now (this is my opinion), it is much harder to find bargains. This is where I like to get the old trusty screener out, d...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol: FF/UMEC/VI) compared to Relvar/Breo Ellipt...
Innoviva (NASDAQ: INVA ): Q1 GAAP EPS of $0.31 misses by $0.05 . More news on: Innoviva, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Total net revenue increased by 5% to $55.2 million in the first quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 60% to $48.5 million in the first quarter of 2019, compared to the same quarter in 2018. Innoviva, Inc. (NASDAQ:INVA) (t...
Many times we use technical analysis in stocks which have for whatever reason been temporarily beaten down. Innoviva, Inc. ( INVA ) is one such stock (commercializes pharmaceuticals) which is still down well over $6 per share from its January highs. Shares though appear to have spent the major...
InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi...
News, Short Squeeze, Breakout and More Instantly...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...